Insider · CIK 0001280044
Maxine Gowen
director
Files at ACRS (Aclaris Therapeutics, Inc.), MRUS (Merus N.V.), PASG (Passage BIO, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 6, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +4,793 | - | - | 21,754 | Jun 9, 2025 |
| Jun 5, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +42,350 | $0.00 | $0 | 42,350 | Jun 9, 2025 |
| Jun 5, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +11,580 | $0.00 | $0 | 11,580 | Jun 9, 2025 |
| Jun 6, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -4,793 | $0.00 | $0 | 0 | Jun 9, 2025 |
| May 28, 2025 | PASG Passage BIO, Inc. | AGrant or award Director Stock Option (right to buy)derivative | +201,857 | $0.00 | $0 | 201,857 | May 30, 2025 |
| May 22, 2025 | MRUS Merus N.V. | AGrant or award Share Option (right to buy)derivative | +13,193 | $0.00 | $0 | 13,193 | May 27, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.